Login to Your Account



Dynavax Shares Rocket After FDA Lifts Hold on Heplisav

By Donna Young


Friday, September 11, 2009
Shares of Dynavax Technologies Corp. soared 45.7 percent Thursday after the FDA lifted a clinical hold on the company's investigational hepatitis B vaccine Heplisav, an immunostimulatory sequence targeting Toll-like receptor 9 (TLR9) combined with hepatitis B surface antigen, finally giving the biotech some good news after 18 months of tribulations. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription